Resultado da Busca
Stephen J. Lippard In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy , Stephen B. Howell, Ed., Plenum Press: New York, 1-12 (1991). X-ray Absorption, Mössbauer, and EPR Studies of the Dinuclear Iron Center in the Hydroxylase Component of Methane Monooxygenase .
3 de nov. de 2014 · Professor Stephen J. Lippard, the Arthur Amos Noyes Professor of Chemistry, has been selected to receive the 2015 Benjamin Franklin Medal in Chemistry for his pioneering research and wide-ranging contributions to the field of bioinorganic chemistry, including protein structure determination, active site characterization, and mechanistic studies by a wide range of physical methods, and the ...
Professor Lippard's research activities span the fields of inorganic chemistry, biological chemistry, and neurochemistry. Included are studies to understand and improve platinum anticancer drugs, the synthesis of diiron complexes as models for carboxylate-bridged diiron metalloenzymes, structural and mechanistic investigations of bacterial multicomponent monooxygenases, and investigations of ...
16 de mai. de 2013 · Stephen J. Lippard, who is widely acknowledged as one of the founders of the field of bioinorganic chemistry, is this year’s recipient of MIT’s James R. Killian Jr. Faculty Achievement Award. Established in 1971 to honor MIT’s 10th president, the Killian Award recognizes extraordinary professional achievements by an MIT faculty member.
Name: Born: Stephen J. Lippard 12 October 1940. Main research interests: Inorganic chemistry, bioinorganic chemistry, and neurochemistry. Synthesis, reactivity, and structure determination of transition metal complexes; mechanism of action of platinum anticancer drugs; chemistry and catalysis at diiron centers; methane monooxygenase; zinc and ...
View Stephen Lippard’s profile on LinkedIn, a professional community of 1 billion members. General Manager, Garner Corral Inc · Experience: Golden Corral Corporation · Education: ...
- Golden Corral Corporation
11 de fev. de 2016 · The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved ...
